Unique Features of Nasal Airway and Airflow Improvement Post‐Dupilumab: A Computational Cohort Study
The Laryngoscope · 2026
DOI: 10.1002/lary.70542 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Laryngoscope, 2026. Verfasst von Ahmad Odeh und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Otolaryngology-Head and Neck Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Rhinosinusitis, Antibodies, Monoclonal, Humanized, Nasal Cavity, Nasal Polyps. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDCD NIH HHS, National Institute on Deafness and Other Communication Disorders (NIH-NIDCD).
Abstract (Originalsprache)
Objective
Dupilumab is a monoclonal antibody approved for treatment of chronic rhinosinusitis (CRS) with nasal polyps, yet literature is sparse regarding its precise effect on nasal airway patency and airflow patterns. This study applied Computational Fluid Dynamics (CFD) modeling to examine the relationship between the changes in nasal structures and aerodynamics and the changes in symptoms after dupilumab treatment.
Methods
Twelve patients enrolled, completed the Sinonasal Outcomes Score (SNOT‐22), as well as CT scans pre and 3 or more months post‐dupilumab treatment. Patient‐specific CFD models were constructed, and Lund‐Mackay (LM) scores were calculated.
Results
Nasal airway cross‐sectional area (CSA) and airflow rate (AFR) in the middle and superior but not inferior meatuses significantly increased posttreatment (all p < 0.05). These increases correlated with SNOT‐22 scores (CSA: r = 0.49, AFR: r = 0.41, p < 0.05), as well as with one question in SNOT‐22, decreased sense of smell/taste (CSA: r = 0.32–0.54, AFR: r = 0.29–0.53, p < 0.05), which may explain previously reported rapid improvement in olfaction post‐dupilumab. Surprisingly, nasal resistance did not significantly decrease posttreatment ( p = 0.12) nor significantly correlate with symptom scores. LM scores significantly improved post‐dupilumab (14.4 ± 6.3 to 9.8 ± 4.6; p < 0.05), with moderate residual inflammation. LM significantly correlated with SNOT‐22 scores ( r = 0.46, p < 0.05), but not with smell/taste complaints.
Conclusion
The impact of dupilumab on nasal airway patency and airflow is not uniform. It is more pronounced in the middle and superior, but not inferior meatus. These unique regional changes significantly correlate with and potentially drive the improvement in patient symptoms. Level of Evidence 3.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Department of Otolaryngology-Head and Neck Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
ORCID-Profile: Ahmad Odeh, Zhenxing Wu, Kai Zhao
Förderung
- NIDCD NIH HHS
- National Institute on Deafness and Other Communication Disorders (NIH-NIDCD)
Zitieren
APA
Odeh, A., Wu, Z., Jha, N., Schneller, A. R., Mihalich, J., Root, Z. T., Brooks, C., Curtis, C., Kraft, M., Wada, K., Otto, B. A., Kelly, K. M., & Zhao, K. (2026). Unique Features of Nasal Airway and Airflow Improvement Post‐Dupilumab: A Computational Cohort Study. The Laryngoscope. https://doi.org/10.1002/lary.70542
Vancouver
Odeh A, Wu Z, Jha N, Schneller AR, Mihalich J, Root ZT, et al. Unique Features of Nasal Airway and Airflow Improvement Post‐Dupilumab: A Computational Cohort Study. The Laryngoscope. 2026. doi:10.1002/lary.70542
BibTeX
@article{Odeh2026,
author = {Odeh, Ahmad and Wu, Zhenxing and Jha, Nidhi and Schneller, Aspen R and Mihalich, James and Root, Zachary T and Brooks, Christopher and Curtis, Casey and Kraft, Monica and Wada, Kara and Otto, Bradley A and Kelly, Kathleen M and Zhao, Kai},
title = {Unique Features of Nasal Airway and Airflow Improvement Post‐Dupilumab: A Computational Cohort Study},
journal = {The Laryngoscope},
year = {2026},
doi = {10.1002/lary.70542}
}
EUVIMED